GlassScriptPhysician profile
Kaetlyn Tharp
NPI 1043986045
$1,922.89
in general payments reported to CMS, 2019-2025
22 companies · $1,102 in 2025
The $1,102 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $17.30 · 2022: $115 · 2023: $544 · 2024: $145 · 2025: $1,102.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,791.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,790.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $709.71 | 2021-2025 | |
| Novo Nordisk INC | $241.17 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $158.89 | 2025 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $117.55 | 2023-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $113.51 | 2022-2025 | Mounjaro, Zepbound |
| Amgen INC. | $85.87 | 2022-2025 | Evenity, Otezla, Repatha |
| Esperion Therapeutics, INC. | $57.12 | 2025 | Nexletol |
| Exact Sciences Corporation | $48.93 | 2023-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $46.66 | 2025 | Veozah |
| Janssen Pharmaceuticals, INC | $42.93 | 2023-2025 | Spravato, Xarelto |
| Ucb, INC. | $42.78 | 2025 | Rystiggo |
| Corcept Therapeutics | $38.41 | 2025 | Korlym |
| Aimmune Therapeutics, INC. | $35.26 | 2025 | Zenpep |
| Phathom Pharmaceuticals, INC. | $30.77 | 2025 | Voquezna |
| Axsome Therapeutics, INC. | $28.75 | 2025 | Auvelity |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $20.41 | 2024 | Dexcom G6 Transmitter |
| Horizon Therapeutics Plc | $19.53 | 2023 | Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $18.91 | 2025 | |
| Biomarin Pharmaceutical INC. | $18.85 | 2025 | Voxzogo 1.2mg |
| Tandem Diabetes Care, INC. | $16.36 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Pfizer INC. | $15.83 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.69 | 2025 | Caplyta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kaetlyn Tharp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.